Literature DB >> 32133135

Stability study of hydromorphone and bupivacaine mixture by HPLC-UV.

Charlotte Macorigh1, Vincent Guibbert1, Marine Casanova1, Catherine Haenni1.   

Abstract

Objectives: The objective of this study was to evaluate the physical and chemical stability of hydromorphone hydrochloride and bupivacaine hydrochloride in concentrations of 15 mg.ml-1 and 10 mg.mL-1 in 0.9% sodium chloride injection. Test samples of hydromorphone/bupivacaine mixtures were stored at 37°C, body temperature encounterd during continuous intrathecal infusion, for 90 days. The solutions were packaged in 20 ml plastic syringes. Evaluations for physical and chemical stability were performed initially and throughout the storage periods. Physical stability was assessed by visual observation. The chemical stability of the drug was evaluated by means of a stability-indicating high-performance liquid chromatographic (HPLC) analytical technique. In addition, pH and osmolarity were measured electronically.
Methods: This study determines the stability and compatibility of hydromorphone (15 mg.ml-1) and bupivacaine (10 mg.ml-1) mixture after 3 months at 37°C using a validated method by HPLC-UV. A simple, precise, specific and accurate reversed phase high performance liquid chromatographic (RP-HPLC) method was developed and validated. The different analytical performance parameters such as linearity, accuracy, specificity, precision and sensitivity (limit of detection and limit of quantitation) were determined according to International Conference on Harmonisation ICH Q2 (R1) guidelines. RP-HPLC was conducted on a nucleoshell RP18plus (C18 150×4.6 mm with 2.7 µm particle size) column. The mobile phase consisted of buffer A (phosphate buffer (0.05M) pH 4.5) and acetonitrile B. The gradient used for the elution is the following one: time (min)/% of B: 0 min/20%; 1.9 min/50%; 2.5 min /40%; 4.5 min/40%; 5.5 min/20%; and 8 min /20%, and the flow rate was maintained at 1.0ml.min-1 and performed at 35°C. The molecules were monitored using Dionex ultimate 3000, equipped with photo diode array detector (λ=210 nm). Linearity was observed in concentration range of 9-21 mg.l-1 for hydromorphone and 6-14 mg.l-1 for bupivacaine. All the system suitability parameters were found within the range.
Results: The degradation study shows a photolytic degradation compound for hydromorphone and an oxidative degradation compound found for bupivacaine. The stability study shows no visible haze or particulate formation or gas evolution. pH and osmolarity were stable during the 3 months. Colour changed after 2 months, although this colouring is due to hydromorphone, proportional to hydromorphone concentrations and increases with time but it is a well known modification. The quantitative study by HPLC method revealed no significant change in hydromorphone and bupivacaine concentration. There is less than 5% of variability during the 3-month period. Conclusions: Hydromorphone (15 mg.ml-1) and bupivacaine (10 mg.ml-1) were physically and chemically compatible and analysed with HPLC, which revealed no significant change in hydromorphone and bupivacaine concentration in this simulated compatibility study. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  HPLC; bupivacaine; drug stability; hydromorphone; pain management; stability

Year:  2018        PMID: 32133135      PMCID: PMC7043245          DOI: 10.1136/ejhpharm-2018-001553

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  12 in total

1.  Compatibility of bupivacaine hydrochloride with hydromorphone hydrochloride or morphine sulfate.

Authors:  J T Neels
Journal:  Am J Hosp Pharm       Date:  1992-09

2.  Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system.

Authors:  Ashley M Classen; Gary H Wimbish; Thomas C Kupiec
Journal:  J Pain Symptom Manage       Date:  2004-12       Impact factor: 3.612

3.  Stability of bupivacaine hydrochloride and hydromorphone hydrochloride during simulated epidural coadministration.

Authors:  C Christen; C E Johnson; J R Walters
Journal:  Am J Health Syst Pharm       Date:  1996-01-15       Impact factor: 2.637

4.  Stability and compatibility of drug mixtures in an implantable infusion system.

Authors:  F Bianchi; A Ginggen; Y Tardy
Journal:  Anaesthesia       Date:  2008-09       Impact factor: 6.955

Review 5.  Stability and compatibility of morphine.

Authors:  A Vermeire; J P Remon
Journal:  Int J Pharm       Date:  1999-09-30       Impact factor: 5.875

6.  Long-term intrathecal infusion of drug combinations for chronic back and leg pain.

Authors:  N G Rainov; V Heidecke; W Burkert
Journal:  J Pain Symptom Manage       Date:  2001-10       Impact factor: 3.612

7.  Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients.

Authors:  Zvia Rudich; Philip Peng; Edward Dunn; Colin McCartney
Journal:  J Pain Symptom Manage       Date:  2004-12       Impact factor: 3.612

8.  Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system.

Authors:  K R Hildebrand; D D Elsberry; T R Deer
Journal:  Clin J Pain       Date:  2001-09       Impact factor: 3.442

9.  Alternative intrathecal agents for the treatment of pain.

Authors:  S J Hassenbusch; J Garber; E Buchser; S Du Pen; P Nitescu
Journal:  Neuromodulation       Date:  1999-04

10.  Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain.

Authors:  Timothy R Deer; Robert Levy; Joshua Prager; Eric Buchser; Allen Burton; David Caraway; Michael Cousins; José De Andrés; Sudhir Diwan; Michael Erdek; Eric Grigsby; Marc Huntoon; Marilyn S Jacobs; Philip Kim; Krishna Kumar; Michael Leong; Liong Liem; Gladstone C McDowell; Sunil Panchal; Richard Rauck; Michael Saulino; B Todd Sitzman; Peter Staats; Michael Stanton-Hicks; Lisa Stearns; Mark Wallace; K Dean Willis; William Witt; Tony Yaksh; Nagy Mekhail
Journal:  Neuromodulation       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.